Rational design of carbamate-based dual binding site and central AChE inhibitors by a “biooxidisable” prodrug approach: Synthesis, in vitro evaluation and docking studies

Article abstract of DOI:10.1016/j.ejmech.2018.05.057

Herein, we report a new class of dual binding site AChE inhibitor 4 designed to exert a central cholinergic activation thanks to a redox-activation step of a prodrug precursor 3. Starting from potent pseudo-irreversible quinolinium salts AChE inhibitors 2 previously reported, a new set of diversely substituted quinolinium salts 2a-p was prepared and assayed for their inhibitory activity against AChE. Structure-activity relationship (SAR) analysis of 2a-p coupled with molecular docking studies allowed us to determine which position of the quinolinium scaffold may be considered to anchor the phtalimide fragment presumed to interact with the peripheral anionic site (PAS). In addition, molecular docking provided insight on the linker length required to connect both quinolinium and phatlimide moieties without disrupting the crucial role of quinolinium salt moiety within the catalytic active site (CAS); namely placing the carbamate in the correct position to trigger carbamylation of the active-site serine hydroxyl. Based on this rational design, the putative dual binding site inhibitor 4 and its prodrug 3 were synthesized and subsequently evaluated in vitro against AChE. Pleasingly, whereas compound 4 showed to be a highly potent inhibitor of AChE (IC₅₀ = 6 nM) and binds to AChE-PAS to the same extent as donepezil, its prodrug 3 revealed to be inactive (IC₅₀ > 10 μM). These preliminary results constitute one of the few examples of carbamate-based dual binding site AChE inhibitors.

Full text of DOI:10.1016/j.ejmech.2018.05.057

Accepted Manuscript
Rational design of carbamate-based dual binding site and central AChE inhibitors by
a “biooxidisable” prodrug approach: Synthesis, in vitro evaluation and docking studies
Mihaela-Liliana Ţînţaş, Vincent Gembus, Florent Alix, Anaïs Barré, Gaël Coadou, Lina
Truong, Muriel Sebban, Cyril Papamicaël, Hassan Oulyadi, Vincent Levacher
PII:
S0223-5234(18)30488-4
10.1016/j.ejmech.2018.05.057
EJMECH 10468
DOI:
Reference:
To appear in: European Journal of Medicinal Chemistry
Received Date: 16 February 2018
Revised Date: 10 April 2018
Accepted Date: 31 May 2018
Please cite this article as: M.-L. Ţînţaş, V. Gembus, F. Alix, Anaï. Barré, Gaë. Coadou, L. Truong, M.
Sebban, C. Papamicaël, H. Oulyadi, V. Levacher, Rational design of carbamate-based dual binding site
and central AChE inhibitors by a “biooxidisable” prodrug approach: Synthesis, in vitro evaluation and
docking studies, European Journal of Medicinal Chemistry (2018), doi: 10.1016/j.ejmech.2018.05.057.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT
Rational design of carbamate-based dual binding site and central AChE
inhibitors by a “biooxidisable” prodrug approach: synthesis, in vitro evaluation
and docking studies
b
,a
a
a,b
b
Mihaela-Liliana Ţînţaş , Vincent Gembus* , Florent Alix , Anaïs Barré , Gaël Coadou ,
b
b
b
b
,b
Lina Truong , Muriel Sebban , Cyril Papamicaël , Hassan Oulyadi , Vincent Levacher*
a
VFP Therapies, 15 rue François Couperin, 76000 Rouen, France
b
Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France
*
Corresponding authors : Vincent Levacher, tel/fax : +33235522485/+33235522462, e-mail:
vincent.levacher@insa-rouen.fr ; Vincent Gembus, tel/fax : +33235522465/+33235522462, e-
mail: vgembus@vfp-therapies.com
ABSTRACT
Herein, we report a new class of dual binding site AChE inhibitor 4 designed to exert a central
cholinergic activation thanks to a redox-activation step of a prodrug precursor 3. Starting from
potent pseudo-irreversible quinolinium salts AChE inhibitors 2 previously reported, a new set
of diversely substituted quinolinium salts 2a-p was prepared and assayed for their inhibitory
activity against AChE. Structure-activity relationship (SAR) analysis of 2a-p coupled with
molecular docking studies allowed us to determine which position of the quinolinium scaffold
may be considered to anchor the phtalimide fragment presumed to interact with the peripheral
anionic site (PAS). In addition, molecular docking provided insight on the linker length
required to connect both quinolinium and phatlimide moieties without disrupting the crucial
role of quinolinium salt moiety within the catalytic active site (CAS); namely placing the
carbamate in the correct position to trigger carbamylation of the active-site serine hydroxyl.
Based on this rational design, the putative dual binding site inhibitor 4 and its prodrug 3 were
synthesized and subsequently evaluated in vitro against AChE. Pleasingly, whereas

ACCEPTED MANUSCRIPT
compound 4 showed to be a highly potent inhibitor of AChE (IC50 = 6 nM) and binds to
AChE-PAS to the same extent as donepezil, its prodrug 3 revealed to be inactive (IC > 10
5
0
µM). These preliminary results constitute one of the few examples of carbamate-based dual
binding site AChE inhibitors.
Keywords: Acetylcholine esterase inhibitors, Alzheimer, Dual-binding site inhibitor
1
. Introduction
Alzheimer’s disease (AD) is the most common cause of dementia characterized among other
things by the central cholinergic depletion and amyloid-β (Aβ) plaques [1-2]. So far, the use
of acetylcholinesterase (AChE) inhibitors has dominated the symptomatic treatment in early-
to-moderate AD [3]. There are currently three marketed drugs, namely donepezil,
rivastigmine and galantamine. These three molecules, associated in some cases with
memantine (NMDA antagonist glutamate) are the only therapeutic arsenal commercially
available. Much efforts have been devoted these last years to develop dual binding site AChE
inhibitors that simultaneously bind to both catalytic active site (CAS) and peripheral anionic
site (PAS) of the enzyme [4-20]. Indeed, it was postulated that PAS of the enzyme binds to
the nonamyloidogenic form of Aβ protein inducing conformational changes and subsequent
amyloid fibril formation [21-23]. As a result, these new AChE inhibitors are expected to
exhibit a better pharmacological profile in that they may not only alleviate cognitive deficits
but also slow down the progression of AD by inhibiting the Aβ peptide aggregation. Although
these findings triggered a renewed interest in the development for AChE inhibitors, the fact
remains that peripheral activity commonly encountered with AChE inhibitors causes severe
adverse effects and limit seriously their therapeutic efficiency [24]. To address this issue, we
recently reported “biooxidisable” prodrugs 1 derived from rivastigmine with the aim at
improving brain delivery and therapeutic efficacy of AChE inhibitors [25-26]. This prodrug

ACCEPTED MANUSCRIPT
approach is based on the masking of a positive charge which is involved in a cation-π
interaction with Trp84 within the catalytic site of AChE. In contrast to rivastigmine, it is
hypothesized that the dihydroquinoline prodrug 1 remains unprotonated at physiological pH,
thus masking the crucial positive charge while ensuring a good lipophilicity to cross the
blood-brain barrier (BBB). Once in the brain, oxidation of the dihydroquinoline 1 would
unmask the permanent positive charge to restore central AChE inhibition while avoiding the
resulting quinolinium salt 2 to cross back the BBB by passive diffusion (Figure 1a). Although
most carbamate quinolinium salts 2 were potent against hAChE (IC50 up to 10 nM), all
corresponding 1,4-dihydroquinolines proved to be unable to inhibit hAChE (IC > 10 µM),
5
0
providing an in vitro proof of concept of this prodrug approach. In this context, we report
herein the rational design of new central dual binding site AChE inhibitors 4 by exploiting
this “biooxidisable” prodrug approach as depicted in Figure 1b. These dual binding site AChE
inhibitors are expected to restore the cholinergic transmission and prevent the aggregation of
Aβ, all the while avoiding deleterious peripheral effects frequently encountered in the
treatment of AD.
(
a)
Prevent pro-aggregating activity of AChE
Enhance central cholinergic transmission
Redox trapping of the AChE inhibitors 4
O
O
Q+
EWG
O
O
DHQ
N
N
EWG
BBB passive
N
diffusion then [ox]
N
AChE
+
1: IC50>10 µM
2: IC50 < 10 nM
Q+
Ar
linker
(
b)
"locked in"
Ar Aromatic binding to PAS
PAS
gorge
catalytic site
Dual binding site AChE inhibitors 4
NAD(H)
redox-activation
NAD+
passive
diffusion
Ar
linker
DHQ
Ar
linker
DHQ
"
biooxidisable" prodrug 3
"biooxidisable" prodrug 3
No activity on peripheral AChE
Good BBB permeability
periphery
BBB
central

ACCEPTED MANUSCRIPT
Figure 1. Design of central AChE inhibitors by a “biooxidisable” prodrug approach (a) catalytic site AChE
inhibitors (prior work); (b) dual binding site AChE inhibitors (this work).
2. Results and discussion
2.1. Synthesis of quinolinium salts 2a-p
These central dual binding site AChE inhibitors 4 are made up of a carbamate quinolinium
salt moiety connected via a linker to an aromatic fragment to bind to the PAS of AChE. We
had first to figure out how and where to connect the aromatic fragment with the quinolinium
salt moiety. From our previous work [25], some structure-activity relationship (SAR)
information was already available to us to address this challenge; namely that the best AChE
inhibitory activities were obtained when the carbamate group of quinolinium salts 2 is located
at C-5. To probe which region of the inhibitor may be considered to link a spacer without
causing major disruptions on the AChE inhibitory activity, we embarked on the preparation of
a new series of carbamate quinolinium salts 2a-p.
The general synthetic route to target compounds 2a-p involves a classical Friedländer
approach followed by an appropriate multi-step functionalization sequence of the resulting 5-
methoxyquinoline derivatives (Schemes 1-2). Thus, quinoline esters 6a,b were readily
prepared in 70-77% yields by reacting methyl trans-3-methoxyacrylate with 2-
aminobenzaldehyde 5a and 2-aminoacetophenone 5b respectively. Likewise, quinoline
carboxamides 6c,d were prepared from N,N-dimethylacetoacetamide and compounds 5a,b in
6
2-72% yields. The resulting 5-methoxyquinoline esters 6a,b were subjected to O-
demethylation in refluxing concentrated HBr to furnish the corresponding 5-
hydroxyquinoline-3-carboxylic acids 7a,b in 74-80% yields. Furthermore, smooth O-
demethylation of 5-methoxyquinoline-3-N,N-dimethylcarboxamides 6c,d took place by means
of ethanethiol and aluminium chloride [27] and without reacting with the carboxamide

ACCEPTED MANUSCRIPT
function at C-3, thus providing 5-hydroxyquinoline-3-N,N-dimethylcarboxamides 8c,d in 66-
7
6% yields. Additionally, a panel of 5-hydroxyquinoline-3-carboxamides 8a,b,e-k could be
prepared in 61-79% yields from 5-hydroxyquinoline-3-carboxylic acids 7a,b and various
amines in the presence of PyBroP as coupling agent (Scheme 1). Lastly, carbamylation of the
resulting 5-hydroxyquinoline-3-carboxamides 8a-k afforded the corresponding 5-
carbamylated quinoline-3-carboxamides 9a-m in 70-90% yields which were subsequently
quaternized to give rise to the desired target quinolinium salts 2a-p in high yields (85-99%)
(Scheme 2).
Scheme 1. Synthesis of 5-hydroxyquinoline-carboxamides 8a-k.
Scheme 2. Access to quinolinium salts 2a-p - carbamylation and quarternization steps.

ACCEPTED MANUSCRIPT
2.2. In vitro evaluation of compounds 2a-p, SAR analysis and docking
In vitro hAChE inhibitory activity of these new quinolinium salts 2a-p was evaluated using
the classical Ellman’s assay [28]. Preliminary SAR analysis indicated that substitution at C-2
or/and C-4 by a methyl group resulted in a complete loss of AChE inhibitory activity (Fig.
2
a). Second, the inhibiting activity drops sharply when the N-substituent of the quinolinium
salt increases in size (Fig. 2b). We also looked at the nature of the carbamate and showed that
only N,N-dimethyl carbamate exhibits an AChE inhibitory activity, all structural
modifications at the carbamate moiety leading to a collapse of the AChE inhibitory activity
(Fig. 2c). This finding is likely related to the inhibition mechanism of these pseudo-
irreversible AChE inhibitors, transferring the carbamate moiety to the serine hydroxyl group
at the esterasic site of the enzyme. Interestingly, we investigated the nature of the electron
withdrawing group at C-3 and showed that quite large structural variations at this position are
tolerated without compromising as much hAChE inhibition; IC values ranging from 20 to
5
0
9
3 nM (Fig. 2d). It is worth mentioning that this functional group was deemed essential to
ensure some stability of the corresponding prodrugs 1 at the periphery by protecting the
enamine double bond against electrophilic attack.

ACCEPTED MANUSCRIPT
Figure 2. Structure-activity relationship of carbamate-quinolinium salts 2a-p – In vitro hAChE inhibition assay
(
Ellman’s test).
Analysis of this SAR data prompted us to suggest that the functional group located at C-3 is
likely the most appropriate attachment-point to link the aromatic fragment to the quinolinium
salt. Moreover, this assumption was supported by a molecular docking simulation study of
compounds 2h, 2j, 2k and 2p on TcAChE (PDB ID: 2CKM) (Figure 3A-D). For all
compounds, the docking interactions showed that the carbamate group is pointing towards
Ser200 residue present in the active site of TcAChE. It was also observed a strong nitrogen
cation-π interaction and π-π stacking with Phe330 amino acid and π-π stacking between
quinolinium and indole ring of Trp84. These interactions position the structure of the
quinolinium compounds in the active site such that the substituent in C-3 position is located
near the bottom of the hydrophobic gorge and can thus allow the chain to be elongated
towards PAS.

ACCEPTED MANUSCRIPT
Figure 3. Top-scored poses obtained with Autodock Vina [29] for compounds 2h (A), 2j (B), 2k (C) and 2p (D)
positioned in active site of TcAChE (PDB ID: 2CKM). The compounds and the selected side chains of the
binding site residues are in stick and the protein in cartoon representation. This figure was made with PyMol
[
30].
2.3. Docking, synthesis and in vitro evaluation of compound 4 and its
prodrug 3
Armed with this valuable SAR study, quinolinium-phtalimide heterodimer 4 was proposed as
a putative dual binding site AChE inhibitor (Figure 4). The proposed heterodimeric AChE
inhibitors 4 contain a phtalimide moiety which is clearly highlighted in the literature as being
one of the most popular aromatic fragments for binding to the PAS region of AChE. [31-34]

ACCEPTED MANUSCRIPT
Figure 4. Quinolinium-phtalimide heterodimer 4.
We next examined from a docking simulation study with TcAChE ((PDB ID: 2CKM) whether
the polyethylene glycol (PEG)-based spacer length in heterodimer 4 makes it possible for
quinolinium and phtalimide fragments to simultaneously bind to the CAS and the PAS
respectively. A detailed analysis of the binding mode of the best docked conformation
highlights dual-binding mode of action; while the quinolinium moiety interacts with the CAS
through aromatic interactions with Trp84 and Phe330 leading the carbamate group to point
towards Ser200, the PEG linker goes up the aromatic gorge and the phtalimide core binds by
π-stacking to both Tyr70 and Trp279 PAS residues (Figure 5A). In addition, a docking
simulation of compound 4 with rhAChE (PDB ID: 4EY7) was also achieved and the best-
scored pose confirmed the preceding results; namely strong interactions with both CAS and
PAS amino-acid residues (Figure 5B).
Figure 5. Top-scored poses obtained with Autodock Vina [29] for compound 4 positioned in active site of
TcAChE (Figure 5A, PDB ID: 2CKM) and in rhAChE (Figure 5B, PDB ID: 4EY7). The compounds and the
selected side chains of the binding site residues are in stick and the protein in cartoon representation. This figure
was made with PyMol [30].

ACCEPTED MANUSCRIPT
Supported by these promising predictions, we embarked on the synthesis of quinolinium-
phtalimide heterodimer 4 (Scheme 3). The phtalimide-amine 10 [35] and 5-hydroxyquinoline-
3
-carboxylic acid 7a were treated with CDI to afford the expected quinoline-phtalimide 11a in
3
2% yield. All attempts to increase the yield by using other coupling agents such as HATU or
HBTU failed, leading to poorly reproducible yields and tedious purifications. Subsequent
carbamylation of 11a afforded 5-carbamylated quinoline-phtalimide 11b in good yield (73%)
which was readily converted to the corresponding quinolinium salt 4 in 86 % yield in the
presence of MeOTf as quaternization reagent. Finally, the putative prodrug 3 was obtained by
regioselective 1,4-reduction of 4 with 1-benzyl-1,4-dihydronicotinamide (BNAH).
O
OR
O
X
7a, CDI
O
TFA,H N
N
X
2
NEt , DMF
3
N
N
20°C, 16h
H
O
N
O
1
0: X = -(CH CH O) -
32%
2
2
2
Me NCOCl
2
11a: R = H, X = -(CH CH O) -
2 2 2
K CO CH CN
2
3,
3
reflux, 12h
1
1b: R = CONMe2, X = -(CH CH O) -
2 2 2
73%
MeOTf
CH Cl2
2
20°C, 2h
86%
OCONMe O
OCONMe O
2
2
O
O
X
X
BNAH
N
H
N
N
N
H
CH Cl 36h
N+
TfO-
N
2
2,
O
O
87%
3
: X = -(CH CH O) -
4: X = -(CH CH O) -
2 2 2
2
2
2
hAChE IC50 > 10
M
hAChE IC50 = 6 nM
Scheme 3. Synthesis and hAChE inhibitory activity of dual binding site AChE inhibitor 4 and its prodrug 3.
Pleasingly, whereas ligand 4 showed to be a potent hAChE inhibitor (IC = 6 nM, Ellman’s
5
0
test [28]), its “biooxidisable”prodrug form 3 revealed no inhibitory activity towards the
enzyme (IC > 10 µM). Pleasingly, the prodrug also displayed good permeability in Caco-2
5
0
-6
assay (Papp (A-B) = 11.1x10 cm/s, recovery = 91 %). More importantly, ligand 4 showed to

ACCEPTED MANUSCRIPT
displace propidium iodide from the PAS of hAChE (20%) and to inhibit the Aβ (1-42) self-
aggregation (14% at 10 µM) to the same extent as donepezil [36]. In addition, compound 12
was also prepared by reaction with methyl iodide in acetonitrile at 40°C (Scheme 4). It was
-5
proved to be inactive against hAChE activity, i.e. 35% inhibition at 10 M, confirming the
crucial role of carbamate group in the enhancement of the anti-AChE activity.
Scheme 4. Synthesis and hAChE inhibitory activity of quinolinium 12.
These preliminary in vitro assays allow not only to identify a novel class of highly potent
heterodimeric hAChE inhibitors, but also to consider further development of highly centrally
active dual binding site hAChE inhibitors with increased efficacy and/or decreased side
effects by means of a “biooxidisable” prodrug approach.
3
. Conclusion
From our previous work dealing with central pseudo-irreversible AChE inhibitors based on a
redox-activated prodrug strategy [25-26], a new quinolinium-phtalimide heterodimeric ligand
4
was designed to simultaneously interact with both the active and peripheral sites of AChE.
By means of a SAR study of diverse synthesized quinolinium salts 2a-p and a molecular
docking simulation of compounds 2h, 2j, 2k and 2p, we could determine which position of
the quiniolium ring is the most suitable to attach the PEG linker so that the phtalimide
fragment at its end is able to interact with the PAS of hAChE. After docking simulation of the
designed heterodimer 4 in hAChE showing a possible dual-site binding fashion, ligand 4 was
efficiently prepared and revealed to be highly potent against hAChE activity (IC = 6 nM)
5
0

ACCEPTED MANUSCRIPT
while the corresponding prodrug 3 turned out to be inactive (IC > 10 µM). Moreover, a
5
0
propidium competition assay confirms the interaction of compound 4 at the PAS inducing Aβ
1-42) self-aggregation inhibitory activities. All together, these findings pave the way for the
(
development of novel and side-effects free prodrugs of potent dual binding site AChE
inhibitors for the treatment of amnesic disorders like Alzheimer disease.
4
. Experimental section
.1. General
4
All commercial reagents were used without further purification. The solvents were dried with
appropriate desiccants and distilled prior to use or were obtained anhydrous from commercial
suppliers. Silica gel (60, 230–400 mesh or 70–230 mesh) was used for column
chromatography. Reactions were monitored by thin layer chromatography on silica gel
precoated aluminum plates. UV light at 254 nm or KMnO stains were used to visualize TLC
4
1
13
plates. H, C NMR spectra were recorded using a spectrometer operating at 300 and 75 MHz
respectively. Abbreviations used for peak multiplicities are s: singlet, d: doublet, t: triplet, q:
quadruplet dd = doublet of doublet, br = broad, dq = doublet of quadruplet and m: multiplet.
Coupling constants J are in Hz and chemical shifts are given in ppm and calibrated with
1
DMSO-d or CDCl (residual solvent signals). H NMR spectra obtained in CDCl were
6
3
3
1
3
referenced to 7.26 ppm. C NMR spectra obtained in CDCl were referenced to 77.16 ppm
3
and in DMSO-d were referenced to 39.52 ppm. High-resolution mass spectrometry (HRMS)
6
was carried out on a waters LCT XE spectrometer. Elemental analyses were performed by the
microanalysis service of the University of Rouen and were recorded with a Thermo Scientific
FLASH 2000 analyzer.

ACCEPTED MANUSCRIPT
Derivatives 5a,b were synthesized from 3-anisidine using a previously described
synthesis.[37-38] Compounds 6a, 7a, 2o were prepared according to the same procedure as
we have already reported in the literature. [25]
4
.2. Chemistry
4
.2.1. Methyl 5-methoxy-4-methyl-quinoline-3-carboxylate (6b)
To a solution of ketone 5b (7.73 g, 31.0 mmol) and methyl trans-3-methoxyacrylate (7.4 mL,
8.4 mmol) dissolved in 150 mL of methanol was slowly added 3M aqueous solution of
6
hydrochloric acid (100 mL). The resulting mixture was stirred under reflux for 3 hours, then
cooled to room temperature and neutralized by adding solid Na CO . The aqueous solution
2
3
was extracted with CH Cl (4x150 mL) and the combined organic layers were dried (MgSO ),
2
2
4
filtered and concentrated under vacuum. The crude product was then filtered on silica gel to
◦
afford 5.52 g of quinoline 6b. Pale yellow solid, yield: 77%. Mp 85 C. R = 0.39 (Petroleum
f
1
ether:EtOAc 1:1). H NMR (300 MHz, CDCl )
δ 9.03 (s, 1H), 7.67-7.58 (m, 2H), 6.87 (dd, J
3
1
3
=
7.5 Hz, J = 1.5 Hz, 1H), 3.96 (s, 3H), 3.93 (s, 3H), 3.04 (s, 3H). C NMR (CDCl ) δ 168.0,
3
1
58.6, 150.5, 149.8, 148.7, 130.8, 124.9, 122.4, 120.4, 106.4, 55.7, 52.5, 20.6. HRMS (ESI+)
+
mass calcd for [M+H] C H NO m/z 232.0973, found 232.0964.
1
3
14
3
4
.2.2. General procedure for reaction with N,N-dimethylacetoacetamide (6c-d)
To a solution of aldehyde 5a or ketone 5b (4.0 mmol) and N,N-dimethylacetoacetamide (0.49
mL, 4.0 mmol) dissolved in 20 mL of dioxan was slowly added 37% aqueous hydrochloric
acid (6 mL). The resulting mixture was stirred under reflux for 6 hours, then cooled to room
temperature and neutralized by adding solid K CO . The aqueous solution was extracted with
2
3

ACCEPTED MANUSCRIPT
CH Cl (4x15 mL) and the combined organic layers were dried (MgSO ), filtered and
2
2
4
concentrated under vacuum. The crude product was purified by chromatography on silica gel
to afford quinolines 6c or 6d.
4
.2.2.1. 5-Methoxy-N,N,2-trimethyl-quinoline-3-carboxamide (6c)
1
Pale brown solid, yield: 72%. Mp 126°C. R = 0.15 (EtOAc). H NMR (300 MHz, CDCl )
δ
f
3
8
3
1
.38 (s, 1H), 7.62-7.56 (m, 2H), 6.81 (dd, J = 4.8 Hz, J = 2.7 Hz, 1H), 3.96 (s, 3H), 3.17 (s,
1
3
H), 2.87 (s, 3H), 2.67 (s, 3H) ppm. C NMR (75 MHz, CDCl ) δ 170.0, 155.3, 148.4, 130.3,
3
29.4, 128.7, 120.7, 118.3, 104.3, 55.8, 38.7, 34.9, 23.1 ppm. HRMS (ESI+) mass calcd for
+
[
M+H] C H N O m/z 245.1290, found 245.1279.
14
17
2
2
4
.2.2.2. 5-Methoxy-N,N,2,4-tetramethyl-quinoline-3-carboxamide (6d)
1
Pale brown solid, yield: 62%. Mp 112°C. R = 0.12 (EtOAc). H NMR (300 MHz, CDCl )
δ
f
3
7
3
1
.61-7.52 (m, 2H), 6.83 (dd, J = 7.5 Hz, J = 1.5 Hz, 1H), 3.93 (s, 3H), 3.21 (s, 3H), 2.82 (s,
1
3
H), 2.76 (s, 3H), 2.58 (s, 3H) ppm. C NMR (75 MHz, CDCl ) δ 170.3, 157.9, 154.2, 149.1,
3
41.5, 130.5, 129.5, 121.6, 118.6, 105.5, 55.5, 37.6, 34.5, 22.9, 20.3 ppm. HRMS (ESI+)
+
mass calcd for [M+H] C H N O m/z 259.1446, found 259.1443.
1
5
19
2
2
4
.2.3. 5-Hydroxy-4-methyl-quinoline-3-carboxylic acid (7b)
A solution of ester 6b (5.45 g, 23.6 mmol) in an aqueous solution of HBr (150 mL, 48%) was
heated under reflux for 24 hours. After cooling the reaction mixture to room temperature, the
pH was adjusted to 2 with 2M aqueous NaOH. After filtration of the insoluble matter, the pH
was adjusted between 5 and 6, and the resulting precipitate was filtered off, rinsed with cooled

ACCEPTED MANUSCRIPT
◦
water and dried at 50 C under vacuum to afford 3.55 g of carboxylic acid 7b. Brown solid,
1
yield: 74%. Mp 210°C. H NMR (300 MHz, DMSO-d )
δ 8.89 (s, 1H), 7.55 (t, J = 8.1 Hz,
6
1
3
1
H), 7.44 (d, J = 8.1 Hz, 1H), 7.01 (d, J = 7.5 Hz, 1H), 3.06 (s, 3H) ppm. C NMR (75 MHz,
DMSO-d6)
δ 168.8, 156.9, 150.1, 149.3, 147.1, 131.1, 125.4, 120.1, 118.7, 111.2, 20.0 ppm.
Found: C, 64.9; H, 4.45; N, 6.80. Calc. for C H NO : C, 65.02; H, 4.46; N, 6.89%.
1
1
9
3
4
.2.4. General procedure for demethylation of 5-methoxy-quinolines derivatives with AlCl3
Under Argon Atmosphere, AlCl (1.41 g, 5 equiv) were placed in suspension in 2.5 mL of
3
DCM. The suspension was cooled at 0°C then ethanethiol (1.7 mL, 10.8 equiv) was dropwise
added following by the addition of substrate (1.0 mmol, 1 equiv) in DCM (9 mL). After
stirring overnight at room temperature, a Rochelle’s salt solution was added at room
temperature and the mixture was extracted five times with DCM. The combined organic
phase was dried over MgSO and concentrated under vacuum to give the expected
4
compound.
4
.2.4.1. 5-Hydroxy-N,N,2-trimethyl-quinoline-3-carboxamide (8c)
1
Brown solid, yield: 66%. Mp 95°C. R = 0.09 (EtOAc). H NMR (300 MHz, CDCl )
δ 8.47
f
3
(s, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.35 (t, J = 7.5 Hz, 1H), 6.82 (d, J = 6.6 Hz, 1H), 3.18 (s,
1
3
3
1
H), 2.89 (s, 3H), 2.69 (s, 3H) ppm. C NMR (75 MHz, CDCl ) δ 169.9, 154.5, 153.7, 146.6,
3
32.0, 131.3, 128.2, 118.2, 117.2, 109.9, 39.0, 35.1, 21.9 ppm. HRMS (ESI+) mass calcd for
+
[
M+H] C H N O m/z 231.1133, found 231.1124.
13
15
2
2
4
.2.4.2. 5-Hydroxy-N,N,2,4-tetramethyl-quinoline-3-carboxamide (8d)

ACCEPTED MANUSCRIPT
1
Pale brown solid, yield: 76%. Mp 99°C. R = 0.1 (EtOAc). H NMR (300 MHz, MeOD)
f
δ
4
1
11.05 (br s, 1H), 8.72-8.64 (m, 2H), 8.15 (dd, J = 6.0 Hz, J = 3.0 Hz, 1H), 4.42 (s, 3H),
13
.14 (s, 3H), 4.02 (s, 3H), 3.74 (s, 3H) ppm. C NMR (75 MHz, MeOD)
δ 172.1, 157.7,
55.0, 150.0, 144.5, 131.6, 130.9, 119.8, 118.9, 111.4, 38.2, 34.8, 22.5, 20.5 ppm. HRMS
+
(
ESI+) mass calcd for [M+H] C H N O m/z 245.1290, found 245.1286.
14
17
2
2
4
.2.5. General procedure for amidation of carboxylic acid
A suspension of carboxylic acid 7a or 7b (1.0 mmol) in anhydrous DMA (5 mL) was heated
to 50°C until complete solubilisation then the resulting solution was cooled to -5 °C. Amine
(
1.0 mmol, 1 equiv) and DIEA (0.52 mL, 3.0 mmol) were then added followed by PyBrop
466.2 mg, 1.0 mmol) in one portion. The mixture was then warmed to room temperature and
(
stirred for up to 15 h. Water (3 mL) was added dropwise at 0°C and the mixture was
neutralized with a saturated aqueous solution of ammonium chloride. The product was
extracted with EtOAc (5x) and the combined organic layers washed with brine (2x), dried
over MgSO4 and concentrated under vacuum. The crude product was purified by
chromatography on silica gel to afford amide derivatives.
4
.2.5.1. 5-Hydroxy-N,N-dimethyl-quinoline-3-carboxamide (8a)
1
Pale yellow solid, yield: 61%. Mp 172°C. R = 0.17 (EtOAc). H NMR (300 MHz, DMSO-d )
f
6
δ
10.69 (s, 1H), 8.86 (d, J = 2.1 Hz, 1H), 8.50 (d, J = 2.1 Hz, 1H), 7.62 (t, J = 8.1 Hz, 1H),
1
3
7
.50 (d, J = 8.7 Hz, 1H), 6.98 (d, J = 8.1 Hz, 1H), 3.03 (br s, 6H) ppm. C NMR (75 MHz,
DMSO-d6)
δ
168.0, 153.7, 148.6, 148.5, 131.1, 129.2, 127.8, 119.0, 118.0, 109.1, 34.9 ppm.
+
HRMS (ESI+) mass calcd for [M+H] C H N O m/z 217.0977, found 217.0971.
1
2
13
2
2

ACCEPTED MANUSCRIPT
4
.2.5.2. 5-Hydroxy-N,N,4-trimethyl-quinoline-3-carboxamide (8b)
1
White solid, yield: 67%. R = 0.06 (EtOAc). Mp 241°C. H NMR (300 MHz, DMSO-d )
δ
f
6
1
0.45 (s, 1H), 8.48 (s, 1H), 7.52 (t, J = 8.1 Hz, 1H), 7.43 (dd, J = 8.4 Hz, J = 1.2 Hz, 1H),
1
3
6
.96 (dd, J = 7.5 Hz, J = 1.2 Hz, 1H), 3.06 (s, 3H), 2.80 (s, 3H), 2.74 (s, 3H) ppm. C NMR
(75 MHz, DMSO-d6)
δ
168.5, 156.1, 149.4, 147.1, 140.8, 130.0, 129.8, 120.1, 118.5, 110.6,
+
3
7.7, 34.1, 19.7 ppm. HRMS (ESI+) mass calcd for [M+H] C H N O m/z 231.1133, found
13
15
2
2
2
31.1135.
4
.2.5.3. 5-Hydroxy-N-isopropyl-quinoline-3-carboxamide (8e)
1
Pale yellow solid, yield: 70%. R = 0.1 (EtOAc). Mp >260°C. H NMR (300 MHz, DMSO-d )
f
6
δ
1
1
1
10.81 (br s, 1H), 9.22 (d, J = 2.4 Hz, 1H), 8.99 (d, J = 2.1 Hz, 1H), 8.66 (d, J = 7.8 Hz,
H), 7.63 (t, J = 7.8 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 4.17 (dq, J =
13
3.5 Hz, J = 6.7 Hz, 1H), 1.21 (d, J = 6.6 Hz, 6H) ppm. C NMR (75 MHz, DMSO-d )
δ
6
64.0, 154.3, 149.5, 149.2, 131.6, 130.0, 125.8, 119.0, 118.2, 109.1, 41.1, 22.3 ppm. HRMS
+
(
ESI+) mass calcd for [M+H] C H N O m/z 231.1133, found 231.1129.
13
15
2
2
4
.2.5.4. 5-Hydroxy-N-(2-methoxyethyl)quinoline-3-carboxamide (8f)
1
Pale white solid, yield: 72%. R = 0.12 (EtOAc). Mp 198°C. H NMR (300 MHz, DMSO-d )
f
6
δ
10.79 (s, 1H), 9.23 (d, J = 2.4 Hz, 1H), 8.99 (d, J = 1.8 Hz, 1H), 8.93 (br s, 1H), 7.64 (t, J =
.1 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 3.55-3.46 (m, 4H), 3.29 (s,
8
13
3
H) ppm. C NMR (75 MHz, DMSO-d )
δ
164.9, 154.2, 149.5, 148.9, 131.6, 130.1, 125.3,
6
+
1
19.0, 118.1, 109.1, 70.3, 57.8, 39.4 ppm. HRMS (ESI+) mass calcd for [M+H] C H N O
1
3
15
2
3
m/z 247.1082, found 247.1070.

ACCEPTED MANUSCRIPT
4
.2.5.4. 5-Hydroxy-N-phenyl-quinoline-3-carboxamide (8g)
1
Yellow solid, yield: 71%. R = 0.29 (Petroleum Ether:EtOAc 1:2). Mp > 260°C. H NMR
f
(300 MHz, MeOD) δ 9.30-9.29 (m, 2H), 7.76-7.69 (m, 3H), 7.56 (d, J = 8.7 Hz, 1H), 7.42-
1
3
7
.39 (m, 2H), 7.18 (d, J = 7.5 Hz, 1H), 7.02 (d, J = 7.1 Hz, 1H) ppm. C NMR (75 MHz,
DMSO-d6)
δ
164.1, 154.3, 149.6, 149.2, 139.0, 132.0, 130.7, 128.6, 125.9, 123.8, 120.4,
+
1
19.0, 118.1, 109.3 ppm. HRMS (ESI+) mass calcd for [M+H] C H N O m/z 265.0977,
16
13
2
2
found 265.0965.
4
.2.5.5. Methyl 2-[(5-hydroxyquinoline-3-carbonyl)amino]acetate (8h)
1
White solid, yield: 72%. R = 0.28 (EtOAc). Mp 224°C. H NMR (300 MHz, MeOD)
δ 9.22
f
(d, J = 2.1 Hz, 1H), 9.19 (d, J = 1.8 Hz, 1H), 7.70 (t, J = 8.4 Hz, 1H), 7.57 (d, J = 8.4 Hz,
1
3
1
1
H), 7.01 (d, J = 7.5 Hz, 1H), 4.21 (s, 2H), 3.79 (s, 3H) ppm. C NMR (75 MHz, MeOD) δ
71.8, 168.4, 156.0, 150.7, 149.6, 133.8, 133.1, 126.3, 120.2, 119.5, 110.5, 52.7, 42.3 ppm.
+
HRMS (ESI+) mass calcd for [M+H] C H N O m/z 261.0875, found 261.0882.
1
3
13
2
4
4
.2.5.6. N-Cyclohexyl-5-hydroxy-quinoline-3-carboxamide (8i)
1
Pale yellow solid, yield: 67%. R = 0.42 (EtOAc). Mp > 260°C. H NMR (300 MHz, MeOD)
f
δ
9.16 (d, J = 2.1 Hz, 1H), 9.10 (d, J = 2.4 Hz, 1H), 7.66 (t, J = 8.4 Hz, 1H), 7.53 (d, J = 8.4
Hz, 1H), 6.98 (d, J = 7.5 Hz, 1H), 3.98-3.88 (m, 1H), 2.05-1.96 (m, 2H), 1.90-1.81 (m, 2H),
1
3
1
.77-1.66 (m, 1H), 1.48-1.23 (m, 5H)ppm. C NMR (75 MHz, MeOD) δ 167.3, 155.9, 150.4,
1
49.7, 133.4, 132.8, 127.4, 120.2, 119.4, 110.4, 50.8, 33.7, 26.6, 26.4 ppm. HRMS (ESI+)
+
mass calcd for [M+H] C H N O m/z 271.1446, found 271.1434.
1
6
19
2
2

ACCEPTED MANUSCRIPT
4
.2.5.8. 5-Hydroxy-N-methyl-quinoline-3-carboxamide (8j)
1
Yellow solid, yield: 79%. Mp 200°C (dec.). R = 0.16 (EtOAc). H NMR (300 MHz, MeOD)
f
δ
1
1
9.18 (d, J = 2.4 Hz, 1H), 9.12 (d, J= 2.1 Hz, 1H), 7.66 (t, J = 8.4 Hz, 1H), 7.53 (d, J = 8.7,
1
3
H), 6.98 (d, J = 7.5 Hz, 1H), 2.98 (s, 3H). C NMR (75 MHz, MeOD)
δ 168.5, 155.9,
50.4, 149.5, 133.5, 132.7, 126.7, 120.2, 119.4, 110.4, 27.0 ppm. HRMS (ESI+) mass calcd
+
for [M+H] C H N O m/z 203.0820, found 203.0821.
1
1
11
2
2
4
.2.5.9. 5-hydroxy-N-(2-(2-hydroxyethoxy)ethyl)quinoline-3-carboxamide (8k)
1
Brown solid, yield: 74%. Mp 158-161°C. R = 0.05 (EtOAc). H NMR (300 MHz, DMSO-d )
f
6
δ
10.81 (s, 1H), 9.23 (d, J = 2.3 Hz, 1H), 8.99 (s, 1H), 8.92 (s, 1H), 7.69-7.57 (m, 1H), 7.50
(d, J = 8.5 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 4.61 (t, J = 5.2 Hz, 1H), 3.58 (d, J = 5.4 Hz, 2H),
1
3
3
1
.54-3.43 (m, 6H). C NMR (75 MHz, DMSO-d )
δ
165.1, 154.3, 149.6, 149.1, 131.8, 130.2,
6
+
25.5, 119.1, 118.3, 109.2, 72.2, 68.9, 60.3, 39.4 ppm. HRMS (ESI+) mass calcd for [M+H]
C H N O m/z 277.1188, found 277.1188.
14
17
2
4
4
.2.6. General procedure for carbamylation of compounds 8a-k
To a solution of hydroxyquinoline 8a–k (1.0 mmol) and solid K CO (3.0 mmol) in
2
3
anhydrous DMF (5 mL) was slowly added the corresponding carbamoyl chloride (1.1 mmol)
and the mixture was stirred at room temperature. After completion of the reaction, a saturated
aqueous solution of ammonium chloride (5 mL) was added and the mixture was extracted
with EtOAc (5x5 mL). The combined organic phases were washed with water and brine, dried
over MgSO4 and concentrated under vacuum. The residue was purified by flash
chromatography on silica gel to afford the desired carbamylated quinolines 9a–m.

ACCEPTED MANUSCRIPT
4
.2.6.1. 3-(Dimethylcarbamoyl)-5-quinolyl] N,N-dimethylcarbamate (9a)
1
Viscous oil, yield: 85%. R = 0.05 (EtOAc). H NMR (300 MHz, CDCl )
δ 8.93 (d, J = 2.1
f
3
Hz, 1H), 8.36 (d, J = 1.5 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.72 (t, J = 7.8 Hz, 1H), 7.37 (d, J
1
3
=
7.5 Hz, 1H), 3.21 (s, 3H), 3.15 (s, 3H), 3.03 (s, 6H) ppm. C NMR (75 MHz, CDCl ) δ
3
1
3
69.0, 154.3, 148.7, 148.5, 147.2, 130.2, 129.9, 129.2, 126.6, 121.9, 119.5, 39.7, 37.0, 36.7,
+
5.6 ppm. HRMS (ESI+) mass calcd for [M+H] C H N O m/z 288.1348, found 288.1340.
15
18
3
3
4
.2.6.2. [3-(Dimethylcarbamoyl)-4-methyl-5-quinolyl] N,N-dimethylcarbamate (9b)
1
White solid, yield: 85%. R = 0.06 (EtOAc). Mp > 260°C. H NMR (300 MHz, CDCl )
δ 8.63
f
3
(br s, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.21 (d, J = 7.5 Hz, 1H), 3.16 (s,
1
3
6
H), 3.03 (s, 3H), 2.83 (s, 3H), 2.68 (s, 3H) ppm. C NMR (75 MHz, CDCl ) δ 169.2, 154.9,
3
1
49.3, 148.2, 147.4, 139.6, 131.2, 129.1, 128.1, 122.6, 121.7, 38.5, 37.0, 36.6, 34.8, 18.7 ppm.
+
HRMS (ESI+) mass calcd for [M+H] C H N O m/z 302.1504, found 302.1495.
1
6
20
3
3
4
.2.6.3. [3-(Dimethylcarbamoyl)-2-methyl-5-quinolyl] N,N-dimethylcarbamate (9c)
1
Pale yellow solid, yield: 86%. R = 0.08 (EtOAc). Mp 126°C. H NMR (300 MHz, CDCl )
δ
f
3
8
.00 (br s, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.59 (t, J = 8.4 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H),
1
3
3
.10 (s, 3H), 3.07 (s, 3H), 2.94 (s, 3H), 2.75 (s, 3H), 2.59 (s, 3H) ppm. C NMR (75 MHz,
CDCl3)
δ
169.4, 154.9, 154.0, 148.0, 146.8, 130.3, 129.5, 127.7, 125.6, 120.3, 118.4, 38.4,
+
3
6.7, 36.5, 34.6, 22.8 ppm. HRMS (ESI+) mass calcd for [M+H] C H N O m/z 302.1504,
1
6
20
3
3
found 302.1501.
4
.2.6.4. [3-(Dimethylcarbamoyl)-2,4-dimethyl-5-quinolyl] N,N-dimethylcarbamate (9d)

ACCEPTED MANUSCRIPT
1
Viscous, colorless oil, yield: 82%. R = 0.1 (EtOAc). H NMR (300 MHz, CDCl )
δ 7.91 (d, J
f
3
=
4.8 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.16 (dd, J = 7.5 Hz, J = 0.9 Hz, 1H), 3.20 (s, 3H),
1
3
3
.18 (s, 3H), 3.06 (s, 3H), 2.81 (s, 3H), 2.65 (s, 3H), 2.60 (s, 3H) ppm. C NMR (75 MHz,
CDCl3)
δ
169.5, 154.6, 154.1, 148.5, 147.8, 138.6, 131.2, 128.6, 127.0, 120.7, 120.5, 37.4,
+
3
6.7, 36.3, 34.2, 22.8, 18.4 ppm. HRMS (ESI+) mass calcd for [M+H] C H N O m/z
1
7
22
3
3
3
16.1661, found 316.1650.
4
.2.6.5. [3-(Isopropylcarbamoyl)-5-quinolyl] N,N-dimethylcarbamate (9e)
1
White solid, yield: 76%. R = 0.21 (EtOAc). Mp < 50°C. H NMR (300 MHz, CDCl )
δ 9.15
f
3
(
d, J = 2.1 Hz, 1H), 8.72 (dd, J = 2.1 Hz, J = 0.9 Hz, 1H), 8.01 (dd, J = 8.7 Hz, J = 0.9 Hz,
H), 7.76 (dd, J = 8.4 Hz, J = 7.8 Hz, 1H), 7.39 (dd, J = 7.5 Hz, J = 0.9 Hz, 1H), 6.06 (br d,
J = 7.5 Hz, 1H), 4.35 (dq, J = 13.6 Hz, J = 6.6 Hz, 1H), 3.26 (s, 3H), 3.07 (s, 3H), 1.32 (s, J
1
1
3
=
6.6 Hz, 6H) ppm. C NMR (75 MHz, CDCl ) δ 164.8, 154.9, 149.5, 148.2, 147.5, 130.5,
3
1
30.2, 127.6, 126.5, 121.7, 119.5, 42.4, 37.0, 36.8, 22.8 ppm. HRMS (ESI+) mass calcd for
+
[
M+H] C H N O m/z 302.1504, found 302.1490.
16
20
3
3
4
.2.6.6. [3-(Isopropylcarbamoyl)-5-quinolyl] N-ethyl-N-methyl-carbamate (9f)
1
White solid, yield: 73%. Mp 110°C. R = 0.1 (EtOAc). H NMR of the mixture of two
f
rotamers (300 MHz, CDCl3)
δ 9.10 (s, 1H), 8.61 (s, 0.5H), 8.60 (s, 0.5H), 7.86 (d, J = 8.4
Hz, 1H), 7.67-7.61 (m, 1H), 7.31 (d, J = 7.8 Hz, 0.5H), 7.27 (d, J = 8.7 Hz, 0.5H), 6.71 (br t,
J = 7.2 Hz, 1H), 4.32-4.21 (m, 1H), 3.55 (q, J = 7.2 Hz, 1H), 3.38 (q, J = 7.2 Hz, 1H), 3.17
(s, 1.5H), 2.97 (s, 1.5H), 1.31 (t, J = 7.2 Hz, 1.5H) 1.22 (d, J = 6.6 Hz, 6H), 1.19 (t, J = 6.9
13
Hz, 1.5H) ppm. C NMR of the mixture of two rotamers (75. MHz, CDCl )
δ
164.8, 154.1,
3
1
53.9, 149.3, 148.4, 148.2, 147.4, 130.4, 130.2, 129.9, 127.5, 126.4, 126.3, 121.5, 119.3, 44.3,

ACCEPTED MANUSCRIPT
+
4
3
2.2, 34.5, 34.1, 22.7, 13.5, 12.5 ppm. HRMS (ESI+) mass calcd for [M+H] C H N O m/z
17
22
3
3
16.1661, found 316.1654.
4
.2.6.7. [3-(Isopropylcarbamoyl)-5-quinolyl] pyrrolidine-1-carboxylate (9g)
1
Viscous colorless oil, yield: 71%. R = 0.23 (EtOAc). H NMR (300 MHz, CDCl )
δ
9.14 (d, J
f
3
=
2.1 Hz, 1H), 8.78 (d, J = 2.1 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.77 (t, J = 7.8 Hz, 1H),
7
2
.46 (d, J = 7.5 Hz, 1H), 6.09 (br d, J = 7.8 Hz, 1H), 4.38-4.31 (m, 1H), 3.75 (t, J = 6.6 Hz,
13
H), 3.53 (t, J = 6.6 Hz, 2H), 2.07-1.96 (m, 4H), 1.32 (d, J = 6.6 Hz, 6H) ppm. C NMR (75.
MHz, CDCl3)
δ
164.8, 152.5, 149.3, 148.2, 147.3, 130.5, 130.4, 127.5, 126.1, 121.5, 119.3,
+
4
3
6.7, 46.6, 42.2, 25.8, 24.9, 22.6 ppm. HRMS (ESI+) mass calcd for [M+H] C H N O m/z
18
22
3
3
28.1661, found 328.1662.
4
.2.6.8. [3-(2-Methoxyethylcarbamoyl)-5-quinolyl] N,N-dimethylcarbamate (9h)
1
White solid, yield: 70%. R = 0.06 (EtOAc). Mp 138°C. H NMR (300 MHz, CDCl )
δ 9.19
f
3
(d, J = 1.8 Hz, 1H), 8.69 (d, J = 1.8 Hz, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.72 (t, J = 7.8 Hz,
1
3
1
H), 7.36 (d, J = 7.8 Hz, 1H), 6.97 (br s, 1H), 3.69-3.64 (m, 2H), 3.57-3.53 (m, 2H), 3.36 (s,
1
3
H), 3.21 (s, 3H), 3.02 (s, 3H) ppm. C NMR (75 MHz, CDCl ) δ 165.6, 154.4, 149.7, 148.2,
3
47.6, 130.8, 130.4, 127.2, 126.6, 121.8, 119.7, 71.1, 59.0, 40.0, 37.1, 36.8 ppm. HRMS
+
(
ESI+) mass calcd for [M+H] C H N O m/z 318.1453, found 318.1444.
16
20
3
4
4
.2.6.9. [3-(Phenylcarbamoyl)-5-quinolyl] N,N-dimethylcarbamate (9i)
1
Pale yellow solid, yield: 90%. R = 0.25 (Petroleum Ether:EtOAc 2:1). Mp 205°C. H NMR
f
(300 MHz, acetone-d6) δ 9.99 (br s, 1H), 9.41 (d, J = 1.8 Hz, 1H), 8.93 (d, J = 1.8 Hz, 1H),

ACCEPTED MANUSCRIPT
8
.00 (d, J = 8.7 Hz, 1H), 7.89-7.83 (m, 3H), 7.49 (d, J = 7.2 Hz, 1H), 7.42-7.37 (m, 2H), 7.16
1
3
(
t, J = 7.5 Hz, 1H), 3.31 (s, 3H), 3.04 (s, 3H) ppm. C NMR (75 MHz, acetone-d )
δ
164.9,
6
1
54.8, 150.4, 150.1, 148.8, 140.0, 131.4, 130.6, 129.6, 129.0, 127.0, 124.9, 122.3, 121.0,
+
1
20.4, 37.0, 36.8 ppm. HRMS (ESI+) mass calcd for [M+H] C H N O m/z 336.1348,
19 18 3 3
found 336.1347.
4
.2.6.10. Methyl 2-[[5-(dimethylcarbamoyloxy)quinoline-3-carbonyl]amino]acetate (9j)
1
White solid, yield: 82%. R = 0.05 (EtOAc). Mp 141°C. H NMR (300 MHz, CDCl )
δ
9.27
f
3
(d, J = 2.4 Hz, 1H), 8.76 (d, J = 1.8 Hz, 1H), 8.02 (d, J = 8.7 Hz, 1H), 7.80 (t, J = 7.8 Hz,
1
3
1
H), 7.42 (d, J = 7.8 Hz, 1H), 6.89 (br s, 1H), 4.32 (d, J = 7.8 Hz, 2H), 3.84 (s, 3H), 3.28 (s,
1
3
H), 3.08 (s, 3H) ppm. C NMR (75 MHz, CD CN)
δ 171.0, 166.6, 155.1, 150.2, 149.9,
3
48.7, 131.7, 130.3, 127.2, 126.9, 122.2, 120.6, 52.6, 42.0, 37.0, 36.9 ppm. HRMS (ESI+)
+
mass calcd for [M+H] C H N O m/z 332.1246, found 332.1234.
1
6
18
3
5
4
.2.6.11. [3-(Cyclohexylcarbamoyl)-5-quinolyl] N,N-dimethylcarbamate (9k)
1
Pale yellow solid, yield: 87%. R = 0.36 (EtOAc). Mp 204°C. H NMR (300 MHz, CDCl )
δ
f
3
9
.16 (d, J = 2.1 Hz, 1H), 8.72 (d, J = 1.5 Hz, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.77 (t, J = 7.8
Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 6.18 (d, J = 7.2 Hz, 1H), 4.10-3.95 (m, 1H), 3.27 (s, 3H),
13
3
.07 (s, 3H), 2.14-1.93 (m, 2H), 1.86-1.69 (m, 3H), 1.48-1.21 (m, 5H) ppm. C NMR (75
MHz, CDCl3)
δ
164.7, 154.3, 149.2, 148.3, 147.4, 130.4, 130.1, 127.7, 126.3, 121.5, 119.4,
+
4
3
9.2, 36.9, 36.7, 33.0, 25.5, 25.0 ppm. HRMS (ESI+) mass calcd for [M+H] C H N O m/z
19
24
3
3
42.1817, found 342.1810.
4
.2.6.12. [3-(Methylcarbamoyl)-5-quinolyl] N,N-dimethylcarbamate (9l)

ACCEPTED MANUSCRIPT
1
Pale yellow solid, yield: 89%. Rf = 0.06 (EtOAc). Mp 182°C. H NMR (300 MHz, CDCl )
δ
3
9
.18 (d, J = 2.1 Hz, 1H), 8.72 (d, J = 1.5 Hz, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.77 (t, J = 8.4
Hz, 1H), 7.40 (dd, J = 8.4 Hz, J = 0.9 Hz, 1H), 6.56 (br s, 1H), 3.26 (s, 3H), 3.08 (s, 3H),
1
3
3
1
.05 (d, J = 4.8 Hz, 3H) ppm. C NMR (75 MHz, CDCl3) δ 166.0, 154.5, 148.9, 148.4,
47.3, 130.3, 130.0, 127.1, 126.1, 121.5, 119.3, 36.8, 36.5, 26.7 ppm. HRMS (ESI+) mass
+
calcd for [M+H] C H N O m/z 274.1191, found 274.1189.
1
4
16
3
3
4
.2.6.13. 3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)quinolin-5-yl dimethylcarbamate (9m)
1
White solid, yield: 90%. Rf = 0.06 (EtOAc). Mp 104-106°C. H NMR (300 MHz, CDCl )
δ
3
9
7
3
1
4
3
.22 (d, J = 2.1 Hz, 1H), 8.66 (d, J = 1.9 Hz, 1H), 7.96 (br s, 1H), 7.91 (d, J = 8.5 Hz, 1H),
.68 (appt, J = 8.1 Hz, 1H), 7.31 (d, J = 7.6 Hz, 1H), 3.69-3.64 (m, 2H), 3.64-3.58 (m, 4H),
1
3
.56-3.50 (m, 2H), 3.18 (s, 3H), 2.99 (s, 3H), 2.43 (1H) ppm. C NMR (75 MHz, CDCl )
δ
3
66.0, 154.7, 149.4, 148.9, 147.6, 130.6, 130.4, 127.5, 126.5, 121.8, 119.6, 72.4, 69.7, 61.6,
+
0.2, 37.0, 36.8 ppm. HRMS (ESI+) mass calcd for [M+H] C H N O m/z 348.1559, found
17
22
3
5
48.1558.
4
.2.7. General procedure for quaternarization of compounds 9a-n,p
To a stirred solution of carbamylated quinoline 9a–m (1.0 mmol) in acetonitrile (2 mL) was
added methyl iodide or dimethylsulfate (10.0 mmol) (or ethyl iodide (2.0 mmol), or benzyl
bromide (1.5 mmol)) at room temperature. The resulting mixture was stirred for 17h at 80°C
in sealed tube. After cooling at room temperature, diethylether was added to the mixture and
the resulting precipitate was filtered off, rinsed with diethylether and dried under vacuum to
afford the corresponding quinolinium salt 2a-n,p.

ACCEPTED MANUSCRIPT
4
.2.7.1. [3-(Dimethylcarbamoyl)-1-methyl-quinolin-1-ium-5-yl] N,N-dimethylcarbamate
iodide (2a)
1
Red solid, yield: 94%. Mp 222°C (dec.). H NMR (300 MHz, CDCl )
δ
10.00 (s, 1H), 9.00 (s,
3
1
3
1
3
3
H), 8.30 (d, J = 8.7 Hz, 1H), 8.20 (t, J = 8.7 Hz, 1H), 7.76 (d, J = 7.5 Hz, 1H), 4.82 (s, 3H),
13
.25 (s, 3H), 3.23 (s, 3H), 3.10 (s, 3H), 3.02 (s, 3H) ppm. C NMR (75 MHz, CDCl3)
δ
64.0, 152.9, 149.3, 148.8, 139.3, 138.8, 137.0, 130.2, 123.9, 122.9, 115.9, 47.9, 41.1, 37.2,
+
7.1, 36.0 ppm. HRMS (ESI+) mass calcd for [M] C H N O , m/z 302.1504, found
16
20
3
3
02.1502.
4
.2.7.2. [3-(Dimethylcarbamoyl)-1,2-dimethyl-quinolin-1-ium-5-yl] N,N-dimethylcarbamate
iodide (2b)
1
Red viscous oil, yield: 93%. H NMR (300 MHz, CDCl )
δ
8.71 (s, 1H), 8.17-8.07 (m, 2H),
3
7
3
1
.76 (dd, J = 6.9 Hz, J = 4.5 Hz, 1H), 4.66 (s, 3H), 3.26 (s, 6H), 3.25 (s, 3H), 3.23 (s, 3H),
1
3
.10 (s, 3H) ppm. C NMR (75 MHz, CDCl3)
δ 165.3, 158.7, 153.0, 148.6, 140.2, 136.7,
36.4, 133.2, 122.7, 122.0, 115.8, 42.9, 40.9, 37.3, 37.1, 35.5, 22.6 ppm. HRMS (ESI+) mass
+
calcd for [M] C H N O , m/z 316.1661, found 316.1668.
17
22
3
3
4
.2.7.3. [3-(Dimethylcarbamoyl)-1,4-dimethyl-quinolin-1-ium-5-yl] N,N-dimethylcarbamate
iodide (2c)
1
Red viscous oil, yield: 94%. H NMR (300 MHz, CDCl )
δ
9.62 (s, 1H), 8.16-8.07 (m, 2H),
3
7
2
.63 (dd, J = 7.2 Hz, J = 1.5 Hz, 1H), 4.74 (s, 3H), 3.24 (s, 3H), 3.21 (s, 6H), 3.10 (s, 3H),
1
3
.96 (s, 3H) ppm. C NMR (75 MHz, CDCl3)
δ 164.2, 153.5, 153.4, 150.4, 147.3, 139.0,

ACCEPTED MANUSCRIPT
1
35.8, 132.4, 125.5, 124.7, 116.9, 48.2, 40.2, 37.4, 37.1, 35.5, 20.9 ppm. HRMS (ESI+) mass
+
calcd for [M] C H N O , m/z 316.1661, found 316.1662.
17
22
3
3
4
.2.7.4. [3-(Dimethylcarbamoyl)-1,2,4-trimethyl-quinolin-1-ium-5-yl] N,N-
dimethylcarbamate iodide (2d)
1
Orange oil, yield: 92%. Mp 159°C. H NMR (300 MHz, CDCl )
δ
8.16-8.03 (m, 2H), 7.55
3
(dd, J = 7.5 Hz, J = 1.2 Hz, 1H), 4.61 (s, 3H), 3.23 (s, 6H), 3.20 (s, 3H), 3.17 (s, 3H), 3.09 (s,
1
3
3
H), 2.88 (s, 3H) ppm. C NMR (75 MHz, CDCl3) δ 165.6, 156.6, 153.5, 151.1, 150.0,
1
40.2, 135.2, 134.4, 124.5, 123.2, 117.1, 43.2, 39.8, 37.2, 36.9, 35.0, 22.9, 20.9 ppm. HRMS
+
(
ESI+) mass calcd for [M] C H N O , m/z 330.1817, found 330.1816.
18
24
3
3
4
.2.7.5. [3-(Isopropylcarbamoyl)-1-methyl-quinolin-1-ium-5-yl] N,N-dimethylcarbamate
iodide (2e)
1
Yellow solid, yield: 99%. Mp 232°C. H NMR (300 MHz, CDCl )
δ
11.0 (s, 1H), 9.65 (s,
H), 8.82 (d, J = 7.2 Hz, 1H), 8.23 (t, J = 8.1 Hz, 1H), 8.07 (d, J = 8.7 Hz, 1H), 7.86 (d, J =
.8 Hz, 1H), 4.83 (s, 3H), 4.46-4.39 (m, 1H), 3.29 (s, 3H), 3.09 (s, 3H), 1.45 (d, J = 6.6 Hz,
3
1
7
6
1
13
H) ppm. C NMR (75 MHz, DMSO-d )
δ 160.3, 152.8, 149.5, 148.1, 142.1, 139.1, 137.4,
6
28.4, 124.0, 122.9, 115.1, 46.9, 43.7, 37.3, 37.1, 22.5 ppm. HRMS (ESI+) mass calcd for
+
[
M] C H N O , m/z 316.1661, found 316.1651.
1
7
22
3
3
4
.2.7.6. [3-(Isopropylcarbamoyl)-1-methyl-quinolin-1-ium-5-yl] N-ethyl-N-methyl-carbamate
iodide (2f)

ACCEPTED MANUSCRIPT
1
Red solid, yield: 99%. Mp 138°C. H NMR of the mixture of two rotamers (300 MHz,
CDCl3)
δ
10.97 (s, 0.5H), 10.95 (s, 0.5H), 9.64 (s, 0.5H), 9.63 (s, 0.5H), 8.74 (t, J = 6.9 Hz,
1
H), 8.27-8.14 (m, 2H), 7.86 (t, J = 7.8 Hz, 1H), 4.85 (2s, 3H), 4.46-4.36 (m, 1H), 3.67 (q, J
=
6.9 Hz, 1H), 3.47 (q, J = 6.9 Hz, 1H), 3.26 (s, 1.5H), 3.07 (s, 1.5H), 1.46-1.36 (m, 7.5H),
1
3
1
1
1
.26 (t, J = 6.9 Hz, 1.5H) ppm. C NMR of the mixture of two rotamers (75 MHz, CDCl ) δ
3
60.2, 160.1, 152.3, 152.2, 149.3, 147.9, 141.8, 139.0, 137.4, 128.2, 128.1, 123.8, 123.7,
22.7, 122.6, 115.2, 115.0, 46.9, 44.6, 44.5, 43.4, 34.6, 34.3, 22.3, 13.4, 12.2 ppm. HRMS
+
(
ESI+) mass calcd for [M] C H N O , m/z 330.1817, found 330.1810.
18
24
3
3
4
.2.7.7. [3-(Isopropylcarbamoyl)-1-methyl-quinolin-1-ium-5-yl] pyrrolidine-1-carboxylate
iodide (2g)
1
Red solid, yield: 98%. Mp 218°C. H NMR (300 MHz, CDCl )
δ
11.07 (s, 1H), 9.71 (s, 1H),
.85 (d, J = 6.9 Hz, 1H), 8.23 (t, J = 8.4 Hz, 1H), 8.05-7.96 (m, 2H), 4.83 (s, 3H), 4.49-3.38
m, 1H), 3.79 (t, J = 6.6 Hz, 2H), 3.56 (t, J = 6.6 Hz, 2H), 2.09-2.00 (m, 4H), 1.47 (d, J =
3
8
(
13
6
H) ppm. C NMR (75 MHz, CDCl3) δ 160.2, 150.6, 149.0, 148.0, 142.1, 141.7, 138.9,
1
37.4, 127.9, 123.5, 122.4, 114.9, 47.0, 46.9, 46.8, 43.4, 25.5, 24.6, 22.2 ppm. HRMS (ESI+)
+
mass calcd for [M] C H N O , m/z 342.1818, found 342.1819.
19
24
3
3
4
.2.7.8. [3-(2-Methoxyethylcarbamoyl)-1-methyl-quinolin-1-ium-5-yl] N,N-
dimethylcarbamate iodide (2h)
1
Yellow solid, yield: 92%. Mp 120°C. H NMR (300 MHz, CDCl )
δ
11.0 (s, 1H), 9.69 (s,
3
1
1
H), 9.02 (br s, 1H), 8.24 (t, J = 8.7 Hz, 1H), 8.16 (d, J = 8.7 Hz, 1H), 7.86 (d, J = 7.8 Hz,
13
H), 4.82 (s, 3H), 3.75 (br s, 4H), 3.40 (s, 3H), 3.29 (s, 3H), 3.08 (s, 3H) ppm. C NMR (75
MHz, CDCl3)
δ
161.5, 152.8, 149.7, 148.5, 142.0, 139.2, 137.6, 128.1, 124.0, 123.0, 114.8,

ACCEPTED MANUSCRIPT
+
7
3
0.3, 58.8, 46.9, 40.1, 37.3, 37.2 ppm. HRMS (ESI+) mass calcd for [M] C H N O , m/z
17 22 3 4
32.1610, found 332.1611.
4
.2.7.9. [1-Methyl-3-(phenylcarbamoyl)quinolin-1-ium-5-yl] N,N-dimethylcarbamate iodide
(2i)
1
Orange solid, yield: 96%. Mp 152°C. H NMR (300 MHz, CD Cl )
δ
10.54 (s, 1H), 10.45 (s,
2
2
1
H), 9.61 (s, 1H), 8.10 (t, J = 8.4 Hz, 1H), 7.92-7.84 (m, 3H), 7.74 (d, J = 7.8 Hz, 1H), 7.17
1
3
(
t, J = 7.8 Hz, 1H), 7.00 (t, J = 7.2 Hz, 1H), 4.60 (s, 3H), 3.20 (s, 3H), 2.96 (s, 3H) ppm. C
NMR (75 MHz, CD Cl )
δ
160.2, 153.1, 150.1, 149.1, 142.6, 139.5, 138.3, 137.8, 129.0,
2
2
+
1
28.2, 125.3, 124.0, 123.1, 121.1, 114.8, 47.0, 37.4 ppm. HRMS (ESI+) mass calcd for [M]
C H N O , m/z 350.1504, found 350.1504.
20
20
3
3
4
.2.7.10. Methyl 2-[[5-(dimethylcarbamoyloxy)-1-methyl-quinolin-1-ium-3-
carbonyl]amino]acetate iodide (2j)
1
Yellow solid, yield: 95%. Mp 240°C (dec.). H NMR (300 MHz, DMSO-d )
δ
9.98-9.90 (m,
6
2
H), 9.57 (s, 1H), 8.46-8.35 (m, 2H), 7.95 (d, J = 8.7 Hz, 1H), 4.70 (s, 3H), 4.21 (d, J = 5.7
1
3
Hz, 2H), 3.70 (s, 3H), 3.27 (s, 3H), 3.03 (s, 3H) ppm. C NMR (75 MHz, DMSO-d )
δ
169.9,
6
1
3
3
62.1, 153.0, 150.7, 148.7, 139.2, 138.5, 136.8, 126.5, 123.1, 123.0, 116.3, 52.0, 46.2, 41.4,
+
6.8, 36.6 ppm. HRMS (ESI+) mass calcd for [M] C H N O , m/z 346.1403, found
17
20
3
5
46.1395.
4
.2.7.11. [3-(Cyclohexylcarbamoyl)-1-methyl-quinolin-1-ium-5-yl] N,N-dimethylcarbamate
iodide (2k)